Permanent Occlusion of Feeding Arteries and Draining Veins in Solid Mouse Tumors by Vascular Targeted Photodynamic Therapy (VTP) with Tookad by Madar-Balakirski, Noa et al.
Permanent Occlusion of Feeding Arteries and Draining
Veins in Solid Mouse Tumors by Vascular Targeted
Photodynamic Therapy (VTP) with Tookad
Noa Madar-Balakirski
1, Catherine Tempel-Brami
1, Vyacheslav Kalchenko
2, Ori Brenner
2, David Varon
4,
Avigdor Scherz
3., Yoram Salomon
1*
.
1Department of Biological Regulation, The Weizmann Institute of Science, Rehovot, Israel, 2Department of Veterinary Resources, The Weizmann Institute of Science,
Rehovot, Israel, 3Department of Plant Sciences, The Weizmann Institute of Science, Rehovot, Israel, 4Department of Hematology, Hadassah-Hebrew University Medical
Center, Jerusalem, Israel
Abstract
Background: Antiangiogenic and anti-vascular therapies present intriguing alternatives to cancer therapy. However, despite
promising preclinical results and significant delays in tumor progression, none have demonstrated long-term curative
features to date. Here, we show that a single treatment session of Tookad-based vascular targeted photodynamic therapy
(VTP) promotes permanent arrest of tumor blood supply by rapid occlusion of the tumor feeding arteries (FA) and draining
veins (DV), leading to tumor necrosis and eradication within 24–48 h.
Methodology/Principal Findings: A mouse earlobe MADB106 tumor model was subjected to Tookad-VTP and monitored
by three complementary, non-invasive online imaging techniques: Fluorescent intravital microscopy, Dynamic Light
Scattering Imaging and photosensitized MRI. Tookad-VTP led to prompt tumor FA vasodilatation (a mean volume increase
of 70%) with a transient increase (60%) in blood-flow rate. Rapid vasoconstriction, simultaneous blood clotting, vessel
permeabilization and a sharp decline in the flow rates then followed, culminating in FA occlusion at 63.2 sec61.5SEM. This
blockage was deemed irreversible after 10 minutes of VTP treatment. A decrease in DV blood flow was demonstrated, with a
slight lag from FA response, accompanied by frequent changes in flow direction before reaching a complete standstill. In
contrast, neighboring, healthy tissue vessels of similar sizes remained intact and functional after Tookad-VTP.
Conclusion/Significance: Tookad-VTP selectively targets the tumor feeding and draining vessels. To the best of our
knowledge, this is the first mono-therapeutic modality that primarily aims at the larger tumor vessels and leads to high cure
rates, both in the preclinical and clinical arenas.
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Introduction
The distinctive morphological and functional characteristics of
tumor versus normal vasculature [1,2,3], together with its
indispensable role in supporting tumor growth, render the tumor
vasculature an attractive therapeutic target [4,5]. Tumor vessels
are often immature, permeable, highly fractured, architecturally
disordered and lack external smooth muscle and pericyte support.
In addition, the blood flow within demonstrates rheologic
abnormalities, variable pressure and inconsistent flow rates that
upset homeostasis [6,7]. These features enable tumor targeting by
both antiangiogenic therapy and vascular disrupting agents (VDA)
which aim toward inhibition of neovessel recruitment [8] and
destruction of established functional tumor microvessels [9],
respectively. The relatively large, often tortuous feeding arteries
(FA) and draining veins (DV), that transverse the tumor rim [10]
typically remain functional, despite the above therapies and enable
eventual tumor relapse. Consequently, these vessels, which
comprise the tumor lifeline, provide a formidable therapeutic
target for novel anti-vascular treatments such as vascular-targeted
photodynamic therapy (VTP).
VTP generates a local burst of cytotoxic reactive oxygen species
(ROS)uponphoto-activation of acirculating sensitizing agent.Upon
a singletreatmentsession,theROSimpactresultsincompletetumor
vascular destruction. The ultra-short lifetime of ROS confines their
activity to the illuminated volume, sparing downstream tissues from
their toxicity. This antivascular modality appears to exploit the
disparate sensitivities of normal versus pathological vasculature to
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by their chaotic architecture that increases their fragility and retards
blood flow within the pro-thrombotic tumor milieu [11]. Early VTP
approaches required photosensitizer preaccumulation within endo-
thelial cells, leading to damage and impaired endothelial cell
function upon illumination. This approach, based on light-activated
VDAs, has been clinically applied for the treatment of age-related
macular degeneration (AMD) [12] and for the treatment of prostate
cancer in animal models [13,14]. Unfortunately, these protocols
demonstrated limited therapeutic potential and rapid extravagation
of the circulating photosensitizers into adjacent tissues, with
significant consequential lateral damage [12,13,15]. Moreover,
recent studies showed that peripheral tumor blood vessels (e.g. FAs
and DVs) are less sensitive to such VTP approaches [16], consistent
with tumor relapse.
We have developed an innovative approach to VTP by applying
the novel Palladium-Bacteriochlorophyll derivatives, Tookad
[17,18,19] and WST11 (Tookad solubleH), as ROS-generating
agents [15,20,21,22,23]. These sensitizers, defined as laser-
activated vascular occluding agents (VOA), remain confined
within the circulation even at high doses, fail to extravagate to
other tissues/organs, and are rapidly cleared by hepatic and renal
systems. Thus, Tookad-based photoactivation and ROS genera-
tion are intravascular and do not target specific tumor cells or
signaling pathways therein. The respective ROS consist of
superoxide and hydroxyl radicals, rather than singlet oxygen the
prevalent ROS in other VTP approaches [24,25]. These two
species have been reported to initiate pathophysiological processes
leading to vessel impairment and occlusion [26,27], previously
unexplored in the context of photodynamic therapy.
Following a single illumination session, treatment success of up
to 75% can be achieved, as monitored in luciferase-transfected
tumor-bearing mice 24 h post-VTP [21]. Tumor necrosis was
observed 24–48 h later, and eradication and healing several weeks
thereafter [17,18,28]. Tookad-VTP has demonstrated significant
clinical efficacy in first- and second-line treatments of patients with
localized prostate cancer [29,30,31,32,33]. WST11-VTP has also
proven effective in AMD animal models [15] and its safety has
been demonstrated in phase I clinical trials. Furthermore, WST11-
VTP has shown promising results in ongoing Phase II clinical trials
for the treatment of localized prostate cancer in patients who have
been under active surveillance. This minimally invasive single-
session protocol, is probably one of the shortest anti-tumor
treatment modalities available to date and most importantly, is not
associated with significant side effects [32,34].
The dramatic hemodynamic changes induced within seconds of
illumination of Tookad or WST11, lies in sharp contrast to the
delayed and temporal vascular arrest (hours/days) observed with
other forms of VTP [12,13], [14], [9]. This difference underscores
the hypothesis that Tookad/WST11-VTP-based vessel occlusion
involves still unkown and fundamentally different mechanisms.
In this study, a thorough temporal dissection of the vascular
response to Tookad-VTP was monitored. The mouse earlobe tumor
model was used to enable the follow-up of vascular anatomyand real-
time hemodynamic changes during illumination. This model
provides easy and non-invasive imaging access to tumor vessels,
enabling the three online imaging techniques used: (i)f l u o r e s c e n t
IntraVital Microscopy (fIVM), (ii) online Dynamic Light Scattering
Imaging(DLSI)and (iii)online photosensitized psMRI [17,35]. These
methods provide complementary, high resolution, temporal infor-
mation of the blood vessels within and around the tumor.
Here we show that a distinct vasodilatative event, followed by
vasoconstriction, blood clot formation and occlusion of the FAs
takes place within the first minute of sensitizer illumination.
Continued illumination (up to 10 min) resulted in irreversible FA
occlusion, while the adjacent normal vessels remained intact or
resumed normal function shortly after treatment completion. This
rapid and unique response suggests a profoundly novel and
effective vascular-occlusion mechanism, outlining the Tookad-
VTP-specific targets and mode of action.
Materials and Methods
Ethics Statement
All animal experiments were conducted at the Weizmann
Institute of Science and approved by the Weizmann Institutional
Animal Care and Use Committee (IACUC).
Animal and tumor models
Cultured MADB106 rat mammary carcinoma cells were s.c.
grafted to the earlobe (3N10
5 per ear) of anesthetized female CD1
nude mice.
Photosensitizers (PS) and llumination protocol
TookadH (10 mg/kg, Steba-Biotech, France) was i.v. adminis-
tered to the tail-vein of tumor-bearing mice. Light (763 nm) was
provided by a 1W diode laser (CeramOptec, Bonn, Germany)
equipped with an optic fiber with a frontal diffuser (FD1, Medlight
S.A, Ecublens, Switzerland), programmed to project a circular
uniform light field (diameter =11.2 mm) with an average intensity
of 150 mW/cm
2. To illuminate the earlobe target, the light beam
was tilted by 20 degrees to enable simultaneous vertical
microscopic observation of the tumor forming an elliptical shape.
The created gradient of light intensities on the long field
dimension, ranged from 155 mW/cm
2, to 141 mW/cm
2 on the
front and rear edges of the field, (150 mW/cm
2 +3%/-6%,
respectively), while on the shorter dimension the intensity was
constant. Uniformity and the gradient intensity slope were verified
on a test screen by computerized digital scanning measurements.
Considering an average tumor diameter of 3 mm, the variation in
light intensity on the tumor surface and the normal surrounding is
expected to remain within the acceptable light intensity variance of
65%. Notably, the threshold light flux for inducing complete
tumor vascular occlusion in this animal model and Tookad dose, is
120 mW/cm
2 (data not shown)
In vivo VTP protocol
Anaesthetized mice were placed on the microscope stage. The
animal position and light beam (visualized with an online pointer
laser, 3 mW, 630 nm) were aligned for optimal operation.
Treatment was initiated with 5 min illumination (Light control,
LC), followed by i.v. PS administration under continuous
illumination (VTP), and completed 10 min later upon switching
the light off. Dark control (PS administration without illumination)
was conducted separately. The illuminated region encompassed
the entire earlobe and included both the tumor and its healthy
surroundings.
fIVM studies
VTP was conducted on the stage of a zoom upright macroscope
(Olympus SZX-RFL2, Japan) equipped with still (AxioCam HRc,
Carl Zeiss, GmbH Germany) and video (Mintron 12V1-EX CCD,
Taiwan) cameras.
Online blood flow tracking
Red Blood Cells (RBC) from a donor CD1-nude mouse were
stained ex vivo with 15 ug/ml 4-(4-(didecylamino)styryl)-N-
VTP-Tumor Vascular Occlusion
PLoS ONE | www.plosone.org 2 April 2010 | Volume 5 | Issue 4 | e10282methylpyridinium-iodide (4-Di-10-ASP, Anaspec, San Jose,
CA, USA) for 40 min at room temperature (RT). Free fluoro-
fophore was washed out by centrifugation (500 g, 10 min).
Stained RBCs were then i.v. injected (to achieve final ,1%
stained RBC in the recipient mouse blood) shortly before video
recording [17]. Leukocytes and platelets were fluorescently
stained by i.v. administration of Rhodamine 6G (0.5 mg/kg), as
previously described [36,37], immediately before photosensitizer
administration.
Angiography
I.V.-injected high molecular-weight dextran-FITC (250 kDa)
served as a pool marker when using a long pass filter (Ex460-490/
Em510 nm). Vasodilatation and vasoconstriction were assessed by
subtraction of video images (time = t) from that of T0 (onset of
illumination), defining the net-change in fluorescence at time =
T0+t. Assuming a cylindrical shape, blood vessel volume (BVV)
was calculated as BVV=(diameter/2)‘2p * unit length.
DLSI studies
Dynamic Light Scattering Imaging (DLSI) was performed as
described earlier [38] using a custom-made laser illumination
ELFI-C unit (10 mW, 670 nm, Elfi-Tech, Rehovot, Israel). As
DLSI of tumor blood vessels is based on the temporal contrast of
intensity fluctuations produced by light scattered from the
illuminated surface, the laser was adjusted to illuminate the mouse
earlobe and was imaged through a zoom-upright macroscope
(SZX-RFL2, Olympus, Tokyo, Japan) equipped with a PixelFly
QE camera (pco. Imaging, Kelheim, Germany).
MRI studies
The anesthetized mouse was catheterized and its ear was gently
attached (double-sided scotch tape) to a Perspex flat carrying
plate over the 1.5 cm surface coil. The mouse ear was covered
with water-based gel for air isolation. Gradient echo
(TR=100 ms, TE=10 ms, flip angle of 30u, time resolution of
90 sec) and T1w Spin echo (TR=250 ms, TE=9 ms) sequences
were conducted inside a horizontal 4.7T Bruker-Biospec
spectrometer using a transmitter 7.5 cm volume coil and a
1.5 cm receiver-only surface coil. Gd-DTPA (0.1 mmol/kg) was
administered via catheter ,20 min after VTP. All experiments in
this study were repeated at least three times and a representative
experiment is presented.
Data analysis
Online video-recordings were analyzed offline using Virtual-
Dub 1.5.10 and ImageJ 1.33u. Light control (LC) blood flow
velocities were defined as 100% and time-to-stasis is presented as
mean time (min) 6 SEM. MRI data processing was conducted
with MATLAB 6.5 software, using home-made programs [35].
Positive changes in BOLD contrast were assigned to increases in
DeoxyHb levels, while decreased MRI signals were assigned to
increases in blood oxygen saturation or in blood flow rates. The
percentage of BOLD activation was calculated pixel-by-pixel
according to the following equation: [% change = (1-image/
average of control) 6100], resulting in the activation maps
presented below.
Histopathology
Tissue samples were excised from euthanized mice 24 h after
treatment, fixed in 3.7% formaldehyde and underwent standard
histological preparation and hematoxylin-eosin staining at the
Weizmann Institute Pathology Service Unit.
Results
Selective response of the tumor vasculature to Tookad-
VTP
Following implantation, distinct adaptation of the earlobe’s
preexisting vascular network transpired, in support of angiogen-
esis-dependent tumor development. Newly formed FA and DV,
functioning as both the portal for inflow and drainage of the tumor
microcirculation were clearly identifiable (double arrows in
Figure 1A). This newly formed network underwent a gross
response to Tookad-VTP (Figure 1A), where signs of edema and
changes in blood vessel morphology were evident in and
immediately around the tumor (Figure 1A, middle panel) within
twenty-four hours of Tookad-VTP. In addition, significant losses
in blood vessel functionality were recorded by Dextran-FITC
angiography. Blood flow arrest was visible in the FAs and DVs, as
evident by absence of the fluorescent marker (Figure 1 Right
panel). Arterioles and venules of similar size and hierarchy in the
adjacent, healthy tissue appeared functional, despite their
concomitant subjection to the complete VTP protocol.
Specificity of the tumor vascular response to VTP was further
demonstrated by the real-time changes in vessel functionality, as
monitored by DLSI (Figure 1B). Here, the selective decline in
tumor perfusion was observed with the progress of Tookad-VTP.
Towards the end of the first minute of illumination, perfusion
ceased in the tumor vessels, while most of the surrounding, healthy
vasculature remained functional until the end of the recording
(5 min, Figure 1B and Video S1).
Histopathology of the treated earlobe/tumor at 24 h post-
treatment, demonstrated tumor necrosis accompanied by hemor-
rhage, edema and vascular congestion in the tumor and tissues
within a 1–2 mm radius of the treated tumor margin. In contrast,
normal tissues at larger distances, but still exposed to the full
treatment protocol, remained viable and intact (Figure 2). These
results suggest heightened susceptibility of the tumor vasculature
including FAs and DVs, to Tookad-VTP.
VTP-induced hemodynamic alterations in the tumor
blood flow
fIVM was applied during Tookad-VTP in attempt to charac-
terize changes in blood flow within FAs, DVs and the tumor
microvasculature. To this end, RBCs from a donor mouse were
fluorescently stained ex vivo and i.v. injected to the recipient mouse
shortly before the video recording. RBC monitoring demonstrated
blood flow arrest in the superficial tumor microvasculature within
the first minute of illumination and did not resume throughout the
remainder of the monitoring session (Video S2). Blood flow
changes in the monitored FA and DV within the illuminated
region, defined as ‘Vascular Junction 1’ (Video S3), showed a
remarkably different pattern; Flow velocities quantified offline at a
10 sec time resolution (Figure 3), demonstrated a sharp decline in
FA flow rate at the onset of VTP, and reached perfusion arrest at a
mean 63.261.5 seconds (n=5) (Figure 3A). Following a short
delay (seconds), intermittent FA blood-flow was observed for 5–
6 min, characterized by irregular spikes and pauses that were
almost simultaneously reflected its paired DV. At tVTP.5 min,
irreversible FA blood flow arrest, coupled with a reversal in DV
blood flow direction was observed in 100% of the monitored cases
(Figure 3A) and remained as such until the end of the data
acquisition period (15–30 min post-VTP). Some normal vessels
within the illuminated domain occasionally underwent constriction
as well, but regained functionality shortly after treatment ending
(range of minutes). Early treatment termination (tVTP=5 min) led
to complete and partial rehabilitation of the FA and DV blood-
VTP-Tumor Vascular Occlusion
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direction (Figure 3B).
Thus, the hemodynamic FA response pattern to VTP is
comprised of at least two distinct phases. The early response
phase includes FA occlusion within ,60 sec of VTP, but is
reversible if the treatment is not completed. The second phase
involves complete and irreversible tumor vasculature collapse that
lasts beyond treatment completion.
To further explore the prompt FA response and the early-
phase hemodynamic parameters, angiography of the treated
area was conducted throughout illumination. An increase in the
vascular-associated fluorescence, peaking at 22 seconds from
onset of illumination was observed within the tumor boundaries,
but not in the arteries that perfused the surrounding normal
tissue (Figure 4 and Video S4). Alterations in FA vessel
diameter, as extrapolated from angiography signals (expressed
as percent changes in blood volume) and blood flow rates within
t h eF Aw e r et h e np l o t t e da saf u n c t i o no ft i m e( F i g u r e5 ) .A
t r a n s i e n ti n c r e a s ei nF Ab l o o df l o wv e l o c i t y ,p e a k i n ga t1 6 0 %o f
pre-illumination rates, was observed 2–6 sec after VTP
initiation (n=5) and followed by an up to 170% elevation in
arterial blood volume that peaked ,20 seconds after VTP
initiation. This phase was then followed by gradual declines in
arterial blood volume and flow rates until vascular shutdown at
60 seconds. Cumulatively, these results suggest that FAs
comprise the primary targets of Tookad-VTP. No significant
vasodilatation was observed in the normal vasculature while, as
mention above, vasoconstriction, if observed, was typically
transient.
Rapid blood clot formation during Tookad-VTP
VTP-induced hemodynamic changes, viewed within the FAs
during the early phases of treatment, were accompanied by blood
clot formation and a gradual increase in the microvasculature
permeability. In order to directly examine vascular clot formation,
circulating leukocytes and platelets were stained in vivo with
Rhodamine6G immediately before sensitizer injection, allowing
for online imaging of fluorescently-labeled blood clots (Video S5).
Formation of blood clots on the inner FA walls, particularly at pre-
capillary bifurcation points, was observed within 25 sec of VTP
onset (Figure 6), followed by blood clot mobilization towards the
interface of the tumor microcirculation, leading to subsequent
vessel occlusion.
BOLD contrast changes during VTP as viewed by psMRI
Fluorescent microscopy-based, online assessment of VTP-
induced hemodynamic changes offers visualization depth that is
limited to the peripheral tissue surface. To overcome this
limitation, we applied psMRI, enabling imaging at practically
any tissue depth [17,35]. Changes in BOLD contrast in the treated
area, as detected online by psMRI, paralleled those monitored
using fIVM techniques (Figure 3). No changes in BOLD contrast
values were observed before treatment onset or during illumina-
tion alone (LC) (Figure 7A). However, the onset of VTP induced a
prompt increase in BOLD contrast signals exclusively in the tumor
area, which continued to rise throughout the illumination phase
and peaked at 30% above baseline values (Figure 7A, n=6). Upon
completion of the treatment protocol, BOLD contrast signals
further intensified, leveling off at .40% above initial signals
Figure 1. Selective occlusion of tumor vasculature following VTP. A. The tumor (t, marked by an ellipse) containing a discrete vascular
bed (vb) is supplied and drained by major FAs and DVs (double arrows). Vascular Junction 1 (vj1) defines the interface between the tumor’s
small vessels (e.g. capillaries, etc.) and the FAs/DVs. Pre-existing, non-tumor vessels (p) can be seen in the surrounding normal tissue. The same
tumor area is depicted in the middle panel 24 h after VTP. The right hand panel is an image captured during angiography follow up at 24 h
post-VTP. Selective loss of tumor blood vessel functionality, as seen by exclusion of the fluorescent marker, was apparent, while normal
vasculature in the surrounding tissue remained functional. B. Dynamic light scattering imaging of a mouse earlobe before, 60 sec and 180 sec
after Tookad-VTP initiation demonstrated selective reduction in tumor perfusion. Towards the end of the treatment (180 sec), no perfusion was
detected in the tumor zone, while the surrounding vasculature remained functional until treatment completion. Images were produced by
temporal contrast calculations and are presented as color-scale coded maps (higher perfusion is illustrated as lighter colors). These images are
clips selected from Video S1. A and B are represented by two individual animals. All other details are described in the Materials and Methods
section.
doi:10.1371/journal.pone.0010282.g001
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Figure 7B and Video S6). These results comply with a vascular
accumulation of deoxyHb, signifying photo-consumption of
oxygen, a reduction in blood-flow rates due to reduced inflow of
fresh oxygenated blood, and reversed flow of deoxyHb-enriched
venal blood. Vascular functionality in the target area was
measured 20 min post-VTP, by dynamic contrast-enhanced
MRI. A loss of vessel functionality was apparent following the
complete VTP protocol (Figure 7C, 10 min). In contrast, upon
early termination of VTP (tVTP=5 min), a resumption of
Figure 2. Histopathology of the Tookad-VTP-treated tumor-bearing earlobe. Hematoxilin-Eosin staining of untreated MADB106 tumor-
bearing ear sections (A–C) compared to Tookad-VTP-treated tumors 24 h post treatment (D–G) are shown. A. (magnification: 610) The untreated
tissue included viable neoplastic cells which formed a small and well-demarcated mass (outlined in black) within the dermis of the pinna. The aural
cartilage is identified by asterisks. The boxed area is further magnified in B (x20) and includes the epidermis (epi), dermis, and the lumen of several
vascular spaces (asterisks). At higher magnifications (C, 640) several blood vessels surrounded by neoplastic cells were identified (lumen identified
with asterisks), where the endothelial cells lining them (arrowheads) were shown to be viable. D. (magnification: 610) 24 h following Tookad-VTP,
necrosis, hemorrhage, edema and vascular congestion in the tumor area were apparent (boxed in i), with only a small degree of similar findings in the
surrounding tissues (boxed in ii). E. Magnified (x20) tumor area of (Di) showed diffuse necrosis and hemorrhage, no identifiable viable neoplastic cells
and a necrotic epidermal layer (epi) above the tumor. The lumen of blood vessels is marked (asterisks). F. Further magnification (x40) showed the
diffuse necrosis which affected all cells and included extravasated red blood cells indicating acute hemorrhage. Two blood vessels were identified
(asterisks) but no viable endothelial cells were seen. G. Magnified (x40) surrounding tissues of (Dii) showed necrotic neoplastic tissue located above
the aural cartilage (car). The dermis below the cartilage (der) was mildly edematous and contained dilated dermal blood vessels (asterisks). Epidermal
cells (epi) and sebaceous gland cells (arrows) contained viable nuclei.
doi:10.1371/journal.pone.0010282.g002
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contrast values to pre treatment values and below (Figure 7A,
lower graph and Video S7). In addition, the vasculature was found
to be fully functional 20 min post-VTP (Figure 7C, 5 min). No
similar hemodynamic changes were observed in the surrounding
tissues. Thus, VTP-associated BOLD contrast signals tightly
correlated with and complemented the hemodynamic changes
measured by both fIVM and DLSI.
Discussion
The advantage of VTP over other systemically administered
anti-vascular approaches lies in its highly localized toxic effects, as
defined by the illuminated region. Tookad-VTP differs from other
VTP modalities in five critical aspects: (1) the sensitizer does not
extravasate from the circulation and, therefore, the impact of VTP
is confined to the vascular lumen regardless of the drug/light
interval; (2) superoxide and hydroxyl radicals, rather than singlet
oxygen, are the key mediators of its photodynamic effect,
consequently inducing a different chemistry of damage; (3) the
prompt ROS impact is within the circulation, and not in vascular
endothelial cells; (4) induction of irreversible vascular collapse and
blood stasis in the tumor is accomplished within a few minutes of
illumination, [17,18] and primarily involves the FAs and DVs at
the tumor rim, and (5) in contrast to other vascular disruptive
approaches, Tookad-VTP achieves tumor ablation as a mono-
therapy, involving initiation of ischemic necrosis with secondary
radical formation as reported in preclinical and clinical studies
[18,32].
In this study, the details of the swift hemodynamic tumor
vasculature response to Tookad-VTP were examined by three
complementary, real-time imaging methods. These techniques
allowed for identification of the affected blood vessels and
sequential delineation of the events leading to tumor blood stasis.
Tumor-FAs comprised the primary target of Tookad-VTP
(Figures 1 and 6), where blood supply to the tumor microcircu-
lation was promptly arrested by local blood clots accumulating at
the tumor FA-capillary interface (Figures 6 and Video S5).
In addition, the response of the tumor vessels to ROS assault
involved prompt and significant FA vasodilatation (Figures 4–5)
Figure 3. VTP-induced changes in tumor blood-flow. Arterial and venous blood flow during the last minute of light control (LC, dark-gray
background), through the full 10 min VTP protocol (A, light-gray background, n=3, representative mouse is shown) or partial, 5 min treatment
protocol (B, light-gray background, n=3, representative mouse is shown) were monitored. Time resolution=10 sec. Baseline (100%) was defined by
the average blood flow value during the 5 min LC subsession. A sharp decline in the FA flow rate, followed by its collapse after ,1 min VTP, was
accompanied with random pauses and reversed venous blood flow (represented as negative flow values). The standard VTP protocol induced
irreversible arterial blood flow arrest, with a concomitant reversal in venous blood flow direction (A), observed to persist until the end of data
acquisition. Early termination (light off at 5 min) led to the rehabilitation of blood flow levels (B).
doi:10.1371/journal.pone.0010282.g003
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(Figures 3–6), culminating in irreversible flow arrest at illumination
times $5 min (Figure 3). The extensive FA and DV vasoconstric-
tion described for Tookad-VTP, were not observed in other VTP
modalities [39] and are suggested to be critical in their irreversible
occlusion. Absence of contractile smooth muscle elements in
tumor vasculature deem it unlikely that tumor capillaries actively
participate in vasodilatation or vasoconstriction processes. Such
activity is more consistent with that of the larger, more developed
FAs and DVs (Figures 4–6). The susceptibility of these vessels to
Tookad-VTP was found to be highly selective, when compared to
their adjacent, healthy counterparts that remained functional,
despite exposure to the same destructive procedure.
The driving force behind transient FA vasodilatation at the
onset of Tookad-VTP is believed to be tightly related to the abrupt
jump in oxygen consumption, coupled with ROS generation
[35,40]. In efforts to restore local normoxia, the hypoxic
vasodilatative state triggers reperfusion of the illuminated area
with oxygenated blood [41,42]. Instantaneous, local release of
nitric oxide (NON), a potent vasodilator, from intravascular pools
[43,44,45] is believed to play a key role in this process, facilitating
the VTP-induced burst in arterial blood flow (Figures 4, 5 and
Video S4). Moreover, the generated NON may further interact
with the photogenerated superoxide and hydroxyl radicals and
consequently play a critical role in the pathophysiological
developments (Gal, Y and Madar-Balakirski, N et. al. 2010, in
preparation), [46,47,48] towards rapid vascular occlusion. Inter-
estingly, when BOLD MRI was recorded in a different tumor
model, a brief, transient signal dip preceded the elevation of
BOLD contrast. This phenomenon was observed within the time
frame of the induced hypoxic vasodilatation (Figure 4), and is likely
related to the transient and short blood-flow burst and re-
oxygenation process (Tempel-Brami et al. 2010, in preparation).
The massive and almost instantaneous blood clot formation
observed in FAs (Figures 6, S4 and S5) appears markedly different
from the thrombus formation observed following VTP with other
agents, proposed to be the consequence of the physical vascular
damage. Extreme vasodilatation and constriction can cause
dramatic changes in local flow conditions, significantly affecting
the transport of molecules to and from the vessel wall. They can
also lead to alternating flow directions within tumor vessels, as was
already described two decades ago [10,49]. Such activity can
induce platelet, erythrocyte and white cell activation, protein
redistribution and accelerated cell aggregation [50]. Blood clots
formed shortly after illumination primarily blocked down stream
flow in FA, subsequently preventing the blood flow from reaching
the unobstructed capillaries (Figure 6). In the absence of arterial
blood supply, a reversal in DV flow back into the tumor
microcirculation is expected, and was indeed observed (Figure 3).
By providing a means to directly monitor vascular oxygen levels,
with no limits to tissue depth, psMRI monitoring of Tookad-VTP-
induced responses complemented the findings obtained by the fast-
capture imaging techniques applied. The increase in BOLD
contrast observed within the tumor boundaries upon initiation of
VTP (Figure 7A–B), correlated with photochemical oxygen
consumption, decreased arterial flow rates (Figures 3, 5) and
blood clot formation (Figure 6). However, despite complete arterial
stasis, sustained increases in post-VTP BOLD contrast signals
were noted in the bulk of the tumor tissue. The timeline of this
increase correlated well with that of the reversed deoxyHb-rich
venous blood flow into the tumor (Figure 3A). Reversed blood flow
from the draining veins into the tumor was described earlier by
others and said to reflect the impaired development of the tumor
vasculature [10]. However, such flow back into the tumor
capillaries suggests they are still open and remain functional long
after full FAs occlusion (Figures 3, 6). The time course of the
BOLD signal also indicates complete oxygen depletion in the
tumor capillaries after .5 minutes of illumination, a significantly
longer interval than that required for the occlusion of the FA
(Figure 7).
Figure 4. Tookad-VTP induced changes in blood vessel diameter
and morphology. Angiography images of the illuminated area,
extracted from Video S4 before treatment and at tVTP=22sec are
presented. Subtraction of the latter from the former is shown in the lower
image. Arrows indicate FAs/DVs. An increase in the vascular-associated
fluorescence(indicatedbydouble-arrows), peakingat22 seconds fromthe
onset of illumination was observed within the tumor boundaries, but not
in the arteries that perfused the surrounding normal tissue.
doi:10.1371/journal.pone.0010282.g004
Figure 5.Tookad-VTP induced increasein arterial bloodflow rate
and volume. Arterial blood flow rates and volumes were monitored in
the tumor FA during VTP. Baseline (100%) was defined by the average of
LC recordings (gray background). Data analyzed at a 2 sec time resolution
is presented as the mean 6 SEM (n=5). A prompt, but transient #60%
increase in arterial blood flow velocity, followed by an up to 70%elevation
in FA blood volume was observed upon initiation of VTP. Approximately
twenty seconds later, a gradual decline in the arterial blood volume and
flow rate was observed to the point of complete vascular collapse,
whereby stasis was observed at tVTP>60 seconds.
doi:10.1371/journal.pone.0010282.g005
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PLoS ONE | www.plosone.org 7 April 2010 | Volume 5 | Issue 4 | e10282Figure 6. Tookad-VTP induced blood clotting. Circulating leukocytes and platelets were stained in vivo with Rhodamine6G immediately before
sensitizer injection and were monitored online throughout the full VTP protocol (images taken from Video S5). Blood clot formation began on the
inner vessel wall within 25 sec of VTP initiation, particularly at the vessel bifurcation points, and was concomitant with vessel constriction. Five
minutes after VTP onset, a newly formed blood clot occluded the FA, and significantly obstructed tumor arterial blood supply. White and gray dashed
lines define arterial and venous boundaries respectively.
doi:10.1371/journal.pone.0010282.g006
Figure 7. VTP-induced changes as seen via BOLD contrast. A. Graphic presentations of percent changes in BOLD contrast before treatment,
during LC (blue background), 10 min-VTP or 5 min–VTP (yellow background – upper and lower graphs, respectively) and after VTP are shown.
Increases in BOLD contrast signals upon VTP remained constant when illumination continued for 10 min, but declined to pretreated values when
illumination was terminated at 5 min. B. T2w image of the ear tumor, normal surrounding tissues and gel is presented. BOLD activation maps of LC,
10 min VTP and 5 min post-VTP are presented (images taken from Video S6). C. Spin-echo T1w images following 10 min or 5 min-VTP are shown. Gd-
DTPA was administered ,20 min post-VTP. The T1w post-injection images were subtracted from the pre-injection images and the difference are
shown (2
nd and 4
th panels). Exclusion of Gd-DTPA following standard 10 min VTP confirmed tumor-blood stasis, while perfusion of Gd-DTPA
following the partial 5 min illumination indicated blood-flow rehabilitation.
doi:10.1371/journal.pone.0010282.g007
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PLoS ONE | www.plosone.org 8 April 2010 | Volume 5 | Issue 4 | e10282Cumulatively, this study marks tumor FAs as the primary target
of Tookad-VTP. Their rapid occlusion leads to subsequent tumor
ablation via a necrotic process, as described by us previously. The
initial success of Tookad-VTP as a mono-therapy for localized
prostate cancer [31,34] is intriguing and strengthens our
mechanistic claims.
Supporting Information
Video S1 Dynamic light scattering imaging of the mouse earlobe
during Tookad-VTP. In this video clip, the images of the mouse
ear blood vessel were produced after temporal contrast calcula-
tions, as previously described (Kalchenko V, Preise D, Bayewitch
M, Fine I, Burd K, Harmelin A. In vivo dynamic light scattering
microscopy of tumour blood vessels. J Microsc. 2007;228:118–122)
and presented as a color coded map (higher perfusion is illustrated
by lighter colors). Normal perfusion is apparent throughout the
untreated control (2120 sec to 260 sec) and light control
(260 sec to 0 sec) periods. Tookad was injected at time zero.
With progression of Tookad-VTP, a selective and gradual
reduction in tumor perfusion was observed (60 sec). Towards the
end of the treatment session (200 sec), absence of perfusion was
detected in the tumor zone alone, while the surrounding
vasculature remained functional throughout. All other details are
described in the Materials and Methods section.
Found at: doi:10.1371/journal.pone.0010282.s001 (5.90 MB AVI)
Video S2 Blood flow in the tumor vascular bed during Tookad-
VTP. Blood flow in the tumor vascular bed was monitored in real-
time using injected fluorescently-labeled erythrocytes (4-Di-10-
ASP) from donor mice. Blood flow in tumor surface vessels
stopped shortly after onset of VTP and did not resume post-VTP
(6.5 minutes) and up to the end of recording session (30 min, data
not shown).
Found at: doi:10.1371/journal.pone.0010282.s002 (3.15 MB AVI)
Video S3 Blood flow in the tumor’s FA and DV during Tookad-
VTP. Blood flow was monitored in real-time using injected
fluorescently-labeled erythrocytes (4-Di-10-ASP) from donor mice.
No significant changes in flow were detected during the light
control phase. Soon after VTP onset (time counter icon turns red),
blood flow velocity in the main vessels decreased, until full vascular
collapse at ,60 sec. At tVTP=2 min, FA flow still had not
recovered and DV blood velocity dramatically decreased, while
the vessels in the surrounding tissue (also exposed to light and
drug) showed normal behavior. Reversed venous blood flow was
evident at tVTP=5 min. Selective, irreversible FA blood stasis and
reversed venous blood flow remained until the end of data
acquisition period, 30 min post-VTP onset.
Found at: doi:10.1371/journal.pone.0010282.s003 (2.66 MB AVI)
Video S4 Tookad-VTP induced changes in vessel morphology.
Angiography of the illuminated area (250-kDa dextran-FITC)
during Tookad-VTP reveals morphological changes primarily in
the tumor boundaries. With progress in VTP, gradual increase in
vascular permeability of the tumor vessels (manifested by
extravasation of the fluorescent pool marker) indicates vessel wall
damage. The observed dark shadows in the tumor microvascu-
lature are attributed to blood clots that exclude and shield the pool
marker fluorescence. Towards protocol completion (the end of the
movie) tumor vessels appear collapsed.
Found at: doi:10.1371/journal.pone.0010282.s004 (4.45 MB AVI)
Video S5 Tookad-VTP induced blood clotting. Circulating
platelets and leukocytes were stained in vivo with Rhodamine
6 G immediately before sensitizer injection. FA and DV at
‘‘vascular junction 1’’ were monitored before and during Tookad-
VTP. Formation of blood clots on the inner FA walls, particularly
at pre-capillary bifurcation points was observed soon after VTP
onset (tVTP=17 sec), and correlated with vessel constriction
(tVTP,34 sec, peaking at tVTP,60 sec). This was followed by
mobilization of blood clots towards the interface of the tumor
microcirculation with subsequent vessel occlusion.
Found at: doi:10.1371/journal.pone.0010282.s005 (1.44 MB AVI)
Video S6 Changes in BOLD contrast during Tookad-VTP.
Change in BOLD contrast during VTP is presented as a sequence
of color-coded activation maps. (Intensity bar is defined in Figure 6).
Upon VTP onset (digits turn red), a sharpincreasein BOLD contrast
was observed in the illuminated tumor zone, while signal changes in
the normal, surrounding tissues were much smaller (increase in
contrastlevelsattheearmarginswasduetogeldryness).Termination
of the light at tVTP=10 min did not lead to a reduction in BOLD
contrast signals. Time resolution of each frame is 90 sec.
Found at: doi:10.1371/journal.pone.0010282.s006 (0.61 MB AVI)
Video S7 Changes in BOLD contrast during the suboptimal
Tookad-VTP protocol. Change in BOLD contrast signals during
VTP is presented as a sequence of color-coded activation maps.
(Intensity bar is defined in Figure 6). Upon VTP onset (digits turn
red), a sharp increase in BOLD contrast signals was observed in
the illuminated tumor zone. Termination of the light at
tVTP=5 min (suboptimal treatment) led to a decline in contrast
levels to their pretreated values and even below. Changes in
BOLD contrast in the normal surrounding tissues were much
smaller (increase in contrast levels at the ear margins was due to
gel dryness). Time resolution of each frame is 90 sec.
Found at: doi:10.1371/journal.pone.0010282.s007 (0.73 MB AVI)
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